Anteris Technologies Global Corp (AVR) Finansal

Anteris Technologies Global Corp. is a structural heart company, which engages in the development and commercialization of medical devices for heart diseases. The company is headquartered in Eagan, Minnesota and currently employs 174 full-time employees. The company went IPO on 2024-12-13. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THV’s single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The Company’s ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system.